Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ajanta Pharma launches...

    Ajanta Pharma launches BP lowering tablets in US

    Written by savita thakur thakur Published On 2016-11-03T14:16:32+05:30  |  Updated On 3 Nov 2016 2:16 PM IST
    Ajanta Pharma launches BP lowering tablets in US

    New Delhi : Drug firm Ajanta Pharma said it has launched in the US market tablets used for lowering blood pressure.


    After the approval of the United States Food and Drug Administration (USFDA), the company has launched Amlodipine + Olmesartan Medoxomil tablets in the US market through its arm Ajanta Pharma USA Inc," the company said in a BSE filing.


    The company's product is a generic version of Daiichi Sankyo Inc's Azor tablets, it added.


    The product has been launched in four strengths 5mg+20mg, 5mg+40mg, 10mg+20mg and 10mg+40mg, Ajanta Pharma said.


    "Amlodipine + Olmesartan Medoxomil tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market," it added.


    In total, the company has 29 Abbreviated New Drug Applications (ANDA) of which 16 are final ANDA approvals, 2 tentative approvals and 11 ANDAs are under review with USFDA, Ajanta Pharma said.


    Shares of the company today closed 1.84 per cent down at Rs 1,960.35 apiece on BSE.

    Abbreviated New Drug ApplicationAjanta PharmaANDAblood pressureBP lowering tabletsDaiichi SankyoUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok